MAOB and Parkinson disease: This could explain the relatively modest effect of selegiline and rasagiline monotherapy in the treatment of Parkinson's disease (Dezsi and Vecsei, 2017), and also raises a concern regarding MAO B inhibition, which would as such increase dopamine autoxidation and subsequent aminochrome formation.